Cargando…

PS103. Search for biomarkers for ketamine response from changes of cytokines in the patients with treatment resistant depression

Detalles Bibliográficos
Autores principales:	Su, Tung-Ping, Chen, Mu-Hong, Li, Cheng-Da, Bai, Ya-Mei, Chang, Annie, Wu, Hui-Ju, Lin, Wei-Chen, Tu, Pei-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616700/ http://dx.doi.org/10.1093/ijnp/pyw043.103

Ejemplares similares

PS60. Associations between Pro-inflammatory cytokines and grey matter/ cortical thickness in patients with bipolar disorder
por: Bai, Ya-Mei, et al.
Publicado: (2016)

Association of Neurofilament Light Chain With the Antidepressant Effects of Low-Dose Ketamine Infusion Among Patients With Treatment-Resistant Depression
por: Lin, Wei-Chen, et al.
Publicado: (2023)

Functional Dysconnectivity of Frontal Cortex to Striatum Predicts Ketamine Infusion Response in Treatment-Resistant Depression
por: Chen, Mu-Hong, et al.
Publicado: (2020)

A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation
por: Su, Tung-Ping, et al.
Publicado: (2023)

Neurofilament Light Chain Is a Novel Biomarker for Major Depression and Related Executive Dysfunction
por: Chen, Mu-Hong, et al.
Publicado: (2021)

PS142. Ketamine is effective in an animal model of treatment resistant depression
por: Pereira, Vitor Silva, et al.
Publicado: (2016)

Effect of intraocular surgery and ketamine on aqueous and serum cytokines
por: Tu, Kyaw Lin, et al.
Publicado: (2007)

International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators
por: Price, Rebecca B., et al.
Publicado: (2022)

A comparison study of metabolic profiles, immunity, and brain gray matter volumes between patients with bipolar disorder and depressive disorder
por: Bai, Ya-Mei, et al.
Publicado: (2020)

Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine
por: Zhou, Yanling, et al.
Publicado: (2021)

PS93. Repeated Low-Grade Inflammation Increases the Risk of Antidepressant-Resistant Depression: A Nationwide Population-Based Cohort Study
por: Li, Cheng-Ta, et al.
Publicado: (2016)

Pathological findings of ketamine ureteritis
por: Wu, Jiann-Der, et al.
Publicado: (2016)

PS125. Functional and morphological changes induced by ketamine in the hippocampus
por: Treccani, Giulia, et al.
Publicado: (2016)

Identifying common and distinct subcortical volumetric abnormalities in 3 major psychiatric disorders: a single-site analysis of 640 participants
por: Tu, Pei-Chi, et al.
Publicado: (2022)

Minutes of PS technical meeting N° 103 held on 7th October 1998
por: Allardyce, B W
Publicado: (1998)

Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder
por: Bai, Ya-Mei, et al.
Publicado: (2016)

PS101. Oral Ketamine for Treatment Resistant Major Depression – A double blind randomized controlled trial
por: Domany, Yoav, et al.
Publicado: (2016)

The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression
por: Hashimoto, Kenji
Publicado: (2014)

Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder
por: Zhan, Yanni, et al.
Publicado: (2020)

Using Minimal-Redundant and Maximal-Relevant Whole-Brain Functional Connectivity to Classify Bipolar Disorder
por: Chen, Yen-Ling, et al.
Publicado: (2020)

Identifying subtypes of bipolar disorder based on clinical and neurobiological characteristics
por: Chen, Yen-Ling, et al.
Publicado: (2021)

Ketamine for bipolar depression: an updated systematic review
por: Fancy, Farhan, et al.
Publicado: (2023)

Major Depressive Disorder and Stroke Risks: A 9-Year Follow-Up Population-Based, Matched Cohort Study
por: Li, Cheng-Ta, et al.
Publicado: (2012)

Identification of common neural substrates with connectomic abnormalities in four major psychiatric disorders: A connectome-wide association study
por: Tu, Pei-Chi, et al.
Publicado: (2020)

PS72. Sibling Risk of Patients with Bipolar Patients in Taiwan: First Large-Scale National Population-Based Study from 2001 to 2011
por: Chang, Wen-Han, et al.
Publicado: (2016)

Effects of ketamine in electroconvulsive therapy for major depressive disorder: meta-analysis of randomised controlled trials
por: Li, Xiao-Mei, et al.
Publicado: (2020)

Symphony No. 103/
por: Haydn, Joseph

How ketamine helps to overcome depression
por: Huynh, Thu N, et al.
Publicado: (2014)

Ketamine and depression: a narrative review
por: Corriger, Alexandrine, et al.
Publicado: (2019)

Esketamine/ketamine for treatment-resistant depression
por: Lacerda, Acioly L.T.
Publicado: (2020)

Efficacy of ketamine therapy in the treatment of depression
por: Mandal, Suprio, et al.
Publicado: (2019)

The effect of ketamine on preventing postpartum depression
por: Alipoor, Mina, et al.
Publicado: (2021)

Ketamine treatment for depression: a review
por: Yavi, Mani, et al.
Publicado: (2022)

Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review
por: Sukhram, Shiryn D., et al.
Publicado: (2022)

Th17 Cells in Depression: Are They Crucial for the Antidepressant Effect of Ketamine?
por: Cui, Meiying, et al.
Publicado: (2021)

CCDC103 as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma
por: Xu, Zhixing, et al.
Publicado: (2023)

Defensin DEFB103 bidirectionally regulates chemokine and cytokine responses to a pro-inflammatory stimulus
por: Harvey, Lauren E., et al.
Publicado: (2013)

PS193. MicroRNAs as biomarkers for treatment-resistant depression
por: Gururajan, A, et al.
Publicado: (2016)

Neurobiological Markers for Predicting Treatment Response in Patients with Bipolar Disorder
por: Chen, Yen-Ling, et al.
Publicado: (2022)

Safety of Repeated Administration of Parenteral Ketamine for Depression
por: Feifel, David, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_13ss5r3cr7vrr36f9rn7n40nfg